Dividend Adjusted Return
Nov 13, 2025 - Nov 13, 2026JNJ 285.75 (+50.3%)
Healthcare 347.93 (+24.3%)
S&P 500 7561.67 (+11.6%)






Stock Rover estimates Johnson & Johnson’s intrinsic (fair) value at $274.19, against a recent price of $285.75, a margin of safety of -4%. Quantitative scores (0–100): Value 63, Quality 95, Growth 79, Sentiment 95. Analyst consensus: Buy.







Fair Value | $274.19 | |
Margin of Safety | -4% |
Value Score 63 Value Score: Our value score looks at EV/EBITDA, P/E, P/S, P/TB (Price/Tangible Book) and EPS Predictability. P/S and P/TB are compared within a sector. Other metrics are compared across all stocks | Quality Score 95 Quality Score: Our quality score compares profitability and balance sheet metrics to find high quality companies using ROIC, Net Margin, Gross Margin, Interest Coverage, and Debt / Equity metrics. |
Growth Score 79 Growth Score: Our growth score looks at the 5 year history and the forward estimates for EBITDA, Sales, and EPS growth, ranking the best companies across all stocks. | Sentiment Score 95 Sentiment Score: Our sentiment score finds stocks in favor by analyzing Short Interest, returns in key periods over the last year, Price vs. 52-wk High, Days Since 52-wk High and MACD signals. |
| JNJ | Industry | S&P 500 | |
|---|---|---|---|
| Value Score | 63 | 69 | 68 |
| Price / Earnings | 43.4 | 34.7 | 24.9 |
| Price / Sales | 7.0 | 5.3 | 3.5 |
| Price / Free Cash Flow | 35.7 | 28.8 | 35.4 |
| Price / Book | 8.4 | 7.5 | 5.6 |
| Price / Tangible Book | - | - | 361.3 |
| EV / EBITDA | 26.7 | 23.6 | 18.1 |
| EPS Predict. Pctl. | 72 | 72 | 71 |
| Piotroski F Score | 5 | 6 | 7 |
| 5‑Year P/E Range | 17.0 43.4 |
| 5‑Year P/B Range | 4.7 8.4 |
| 5‑Year P/S Range | 3.9 7.0 |
| JNJ | Industry | S&P 500 | |
|---|---|---|---|
| Growth Score | 79 | 69 | 79 |
| Sales Growth | |||
| Sales Growth Next Year | 6.5% | 16.7% | 20.6% |
| Sales 1‑Year Chg (%) | 7.8% | 17.5% | 19.3% |
| Sales 3‑Year Avg (%) | 5.9% | 17.0% | 14.8% |
| Sales 5‑Year Avg (%) | 1.7% | 9.4% | 13.3% |
| EPS Growth | |||
| Next Yr. Growth Est. | 4.5% | 35.1% | 15.4% |
| EPS 1‑Year Chg (%) | -36.3% | 26.4% | 44.9% |
| EPS 3‑Year Avg (%) | 11.5% | 37.9% | 20.4% |
| EPS 5‑Year Avg (%) | -0.3% | 23.2% | 15.4% |






LLY | Eli Lilly | $1,285,790 | 46.9 | 0.5% | 23.7% | 42.0% | -16% | 57 | 100 | 80 |
JNJ | Johnson & Johnson | $687,888 | 43.4 | 1.9% | 14.9% | 49.6% | -4% | 63 | 79 | 95 |
ABBV | AbbVie | $521,499 | 50.7 | 2.4% | 8.2% | 30.8% | 1% | 57 | 91 | 87 |
UNH | UnitedHealth Group | $365,093 | 23.3 | 2.3% | 7.9% | 25.8% | -7% | 86 | 79 | 73 |
MRK | Merck & Co | $364,264 | 149.3 | 2.3% | 4.1% | 63.7% | 1% | 61 | 77 | 64 |
NVS | Novartis | $303,124 | 30.6 | 3.0% | 12.7% | 25.4% | 2% | 72 | 80 | 91 |
AZN | AstraZeneca | $286,066 | 26.1 | 1.7% | 18.4% | 5.7% | -2% | 64 | 94 | 94 |
AMGN | Amgen | $251,886 | 27.0 | 2.2% | 12.8% | 42.4% | -10% | 69 | 90 | 89 |
GILD | Gilead Sciences | $208,476 | - | 2.0% | 13.6% | 37.6% | -21% | 61 | 60 | 77 |
NVO | Novo Nordisk | $183,519 | 10.5 | 4.3% | 9.4% | -11.2% | -5% | 85 | 77 | 83 |
PFE | Pfizer | $164,668 | 41.3 | 6.0% | 1.8% | 17.8% | 27% | 72 | 44 | 83 |
BMY | Bristol-Myers Squibb | $129,656 | 14.1 | 4.0% | 11.9% | 36.2% | 27% | 79 | 56 | 91 |
| JNJ | Industry | S&P 500 | |
|---|---|---|---|
| Quality Score | 95 | 79 | 77 |
| Gross Margin | 67.6% | 73.2% | 33.2% |
| Operating Margin | 25.7% | 27.8% | 17.4% |
| Net Margin | 16.2% | 15.2% | 14.2% |
| Return on Assets | 8.1% | 10.5% | 14.1% |
| Return on Equity | 19.7% | 34.8% | 37.7% |
| ROIC | 18.4% | 22.4% | 24.1% |
| JNJ | Industry | S&P 500 | |
|---|---|---|---|
| Sentiment Score | 95 | 65 | 71 |
| 5‑Day Return | 3.5% | 2.6% | 2.5% |
| 1‑Month Return | 14.9% | 13.7% | -3.1% |
| YTD Return | 40.3% | 26.1% | 11.3% |
| 1‑Year Return | 49.6% | 32.2% | 13.4% |
| 3‑Year Return | 110.8% | 73.8% | 77.8% |
| 5‑Year Return | 99.1% | 84.6% | 72.7% |
| Beta 1‑Year | -0.07 | 0.19 | 1.00 |






| JNJ | Industry | |
|---|---|---|
| Forward Dividend Yield | 1.9% | 2.0% |
| Payout Ratio | 79.0% | 42.7% |
| TTM Yield | 1.9% | - |
| Fwd. Div. Per Share | $5.36 | $4.54 |
| Div. 1Y Chg (%) | 3.1% | - |
| Div. 3Y Avg (%) | 4.0% | - |
| Div. 5Y Avg (%) | 4.8% | - |
| Cons. Growth Years | 10+ | - |
| Div. Coverage Ratio | 1.2 | 1.4 |
| Current Ratio | 1.0 |
| Quick Ratio | 0.7 |
| Price | $285.75 |
| Net Cash Per Share | -$11.50 |
| Equity Per Share | $33.87 |
| Debt / Equity | 0.6 |
| Solvency Ratio | 27% |
| Interest Coverage | 19.0 |
| Short % of Float | 0.8% |
| Altman Z‑Score | 4.5 |
| Current Quarter EPS | |
|---|---|
# Up Last 30 days | 1.00 |
# Down Last 30 days | 4.00 |
Mean Estimate | 2.92 |
% Change (30 Days) | -0.82% |
| Next Quarter EPS | |
|---|---|
# Up Last 30 days | 0.00 |
# Down Last 30 days | 2.00 |
Mean Estimate | 2.67 |
% Change (30 Days) | -5.99% |
| Cur Qtr | Next Qtr | Cur Year | Next Year | |
|---|---|---|---|---|
| Latest | $2.92 | $2.67 | $11.12 | $11.62 |
| 30 Days Ago | $2.94 | $2.84 | $11.06 | $12.32 |
| 90 Days Ago | $3.02 | $2.77 | $11.05 | $12.31 |
| % Change (90 Days) | -3.6% | -3.6% | 0.6% | -5.6% |
| Surprise Type | Amount | Percent |
|---|---|---|
| Positive Quarters (> 2%) | 8 | 66.7% |
| Negative Quarters (< 2%) | 0 | - |
| In-Line Quarters (within 2%) | 4 | 33.3% |
| Surprise Type | Announce Date | Period End Date | Actual EPS | Est. EPS | Surprise (%) |
|---|---|---|---|---|---|
| Positive | 10/13/26 | 09/30/26 | $2.59 | $2.53 | 2.4% |
| Positive | 07/15/26 | 06/30/26 | $2.90 | $2.84 | 2.1% |
| In-Line | 04/21/26 | 03/31/26 | $2.70 | $2.67 | 1.1% |
| In-Line | 01/28/26 | 12/31/25 | $2.46 | $2.43 | 1.2% |
| In-Line | 10/21/25 | 09/30/25 | $2.80 | $2.77 | 1.1% |
| Positive | 07/16/25 | 06/30/25 | $2.77 | $2.66 | 4.1% |
| JNJ | Industry | S&P 500 | |
|---|---|---|---|
| Best Monthly Return (5Y) | 13.6% | 13.1% | 9.6% |
| Worst Monthly Return (5Y) | -8.4% | -6.8% | -9.6% |
| Beta 1‑Year | -0.07 | 0.19 | 1.00 |
| Volatility 1‑Year | 0.21 | 0.17 | 0.13 |
| Volatility 1Y Pctl. | 19 | - | - |
| Max Drawdown 1‑Year | -11.0% | -19.7% | -8.8% |
| Max Drawdown 3‑Year | -14.4% | -27.6% | -18.7% |
| Max Drawdown 5‑Year | -18.4% | -30.4% | -24.6% |












ABBV | AbbVie | 87 | 10.3% | 2270.0% | 9.1% | 10.7% | 6.2% | 3.7% |
JNJ | Johnson & Johnson | 47 | 5.9% | -95.7% | 6.5% | 7.8% | 5.9% | 1.7% |
NVS | Novartis | 30 | 4.7% | -68.8% | 6.9% | 1.8% | 7.7% | 1.8% |
UNH | UnitedHealth Group | 23 | -0.4% | 76.1% | 3.1% | 3.3% | 7.7% | 10.0% |
MRK | Merck & Co | 22 | 4.7% | -12.1% | 3.3% | 4.9% | 4.3% | 7.9% |
UNH | UnitedHealth Group | 50 | 23.3 | 17.5 | 13.9 | 0.8 | 3.7 | 10.0 41.4 |
ABBV | AbbVie | 33 | 50.7 | 18.2 | 7.5 | 7.9 | - | 19.0 178.9 |
NVS | Novartis | 18 | 30.6 | 16.1 | 7.9 | 5.4 | 8.1 | 7.0 33.1 |
JNJ | Johnson & Johnson | 9 | 43.4 | 24.6 | - | 7.0 | 8.4 | 17.0 43.4 |
MRK | Merck & Co | 2 | 149.3 | 16.5 | - | 5.4 | 8.1 | 10.9 500+ |
NVS | Novartis | 100 | 74.9% | 25.2% | 17.5% | 11.7% 40.6% | 4.9% 18.5% |
UNH | UnitedHealth Group | 95 | 19.8% | 5.3% | 3.5% | 12.3% 26.0% | 4.1% 9.0% |
JNJ | Johnson & Johnson | 92 | 67.6% | 25.7% | 16.2% | 17.4% 55.0% | 6.5% 14.0% |
MRK | Merck & Co | 85 | 71.8% | 9.2% | 3.6% | 1.0% 38.3% | 0.4% 16.5% |
ABBV | AbbVie | 72 | 73.7% | 36.0% | 15.7% | -100.0% 294.7% | 1.7% 9.3% |
JNJ | Johnson & Johnson | 84 | 0.6 | 19.0 | 0.7 | 48.2% | 27% | 0.8% |
MRK | Merck & Co | 75 | 1.2 | 3.4 | 1.1 | 35.0% | 12% | 1.1% |
NVS | Novartis | 69 | 1.3 | 9.0 | 0.6 | 57.2% | 25% | 0.2% |
ABBV | AbbVie | 55 | - | 5.3 | 0.8 | 64.0% | 16% | 1.0% |
UNH | UnitedHealth Group | 32 | 0.8 | 6.1 | 0.7 | 42.6% | 11% | 1.7% |
NVS | Novartis | 89 | 3.0% | 3.0% | $160.50 | $4.74 | 10+ | 90.0% |
MRK | Merck & Co | 55 | 2.3% | 2.3% | $147.76 | $3.40 | 10+ | 340.0% |
JNJ | Johnson & Johnson | 51 | 1.9% | 1.9% | $285.75 | $5.36 | 10+ | 79.0% |
UNH | UnitedHealth Group | 50 | 2.3% | 2.2% | $407.46 | $9.28 | 10+ | 51.5% |
ABBV | AbbVie | 46 | 2.4% | 2.4% | $295.03 | $6.92 | 10+ | 117.4% |
JNJ | Johnson & Johnson | 98 | 14.9% | 9.6% | 25.3% | 40.3% | 49.6% | -0.07 | 0.21 | 99.2% |
ABBV | AbbVie | 97 | 8.2% | 18.3% | 43.4% | 33.0% | 30.8% | -0.02 | 0.25 | 97.4% |
MRK | Merck & Co | 96 | 4.1% | 9.7% | 32.0% | 43.3% | 63.7% | 0.22 | 0.29 | 94.2% |
NVS | Novartis | 92 | 12.7% | 5.8% | 7.2% | 19.9% | 25.4% | 0.36 | 0.27 | 94.2% |
UNH | UnitedHealth Group | 77 | 7.9% | 2.7% | 2.8% | 25.9% | 25.8% | 0.34 | 0.35 | 88.3% |





2026 Dividends | $5.32 |
11/24/26 | 12/08/26 | Regular | $1.34 |
08/25/26 | 09/08/26 | Regular | $1.34 |
05/26/26 | 06/09/26 | Regular | $1.34 |
02/24/26 | 03/10/26 | Regular | $1.30 |
2025 Dividends | $5.14 |
11/25/25 | 12/09/25 | Regular | $1.30 |
08/26/25 | 09/09/25 | Regular | $1.30 |
05/27/25 | 06/10/25 | Regular | $1.30 |
02/18/25 | 03/04/25 | Regular | $1.24 |
2024 Dividends | $4.91 |
11/26/24 | 12/10/24 | Regular | $1.24 |
08/27/24 | 09/10/24 | Regular | $1.24 |
05/20/24 | 06/04/24 | Regular | $1.24 |
02/16/24 | 03/05/24 | Regular | $1.19 |
2023 Dividends | $4.70 |
11/20/23 | 12/05/23 | Regular | $1.19 |
08/25/23 | 09/07/23 | Regular | $1.19 |
05/22/23 | 06/06/23 | Regular | $1.19 |
02/17/23 | 03/07/23 | Regular | $1.13 |
2022 Dividends | $4.45 |
11/21/22 | 12/06/22 | Regular | $1.13 |
08/22/22 | 09/06/22 | Regular | $1.13 |
05/23/22 | 06/07/22 | Regular | $1.13 |
Ex-Dividend Date | 11/24/26 |
Payment Date | 12/08/26 |
Amount | $1.34 |
Type | Regular |
Regular Dividend | $1.34 |
Forward Dividend Rate | $5.36 |
Forward Dividend Yield | 1.9% |
Trailing 12 Months Dividends | $5.28 |
Trailing 12 Months Yield | 1.9% |
Payout Ratio | 79.0 |
Dividend Coverage Ratio | 1.2 |
Consecutive Growth Years | 10+ |
3 Year Growth Rate | 4.0% |
5 Year Growth Rate | 4.8% |
10 Year Growth Rate | 5.3% |
Price / Earnings | 43.4 | 20.9 | 23.0 | 30.0 | 24.6 |
Price / Cash Flow | 26.7 | 19.6 | 14.8 | 19.0 | 20.9 |
Price / Book | 8.4 | 6.0 | 5.2 | 5.1 | 5.8 |
Price / Tangible Book | - | - | - | 500+ | 500+ |
Price / Sales | 7.0 | 5.2 | 4.4 | 4.0 | 4.7 |
EV / EBITDA | 26.7 | 12.6 | 15.0 | 16.8 | 18.6 |
Forward Dividend Yield | 1.9% | 2.7% | 3.2% | 3.2% | 2.7% |
Shareholder Yield | 3.0% | 3.6% | 3.9% | 3.8% | 4.0% |
Gross Margin | 67.6% | 68.1% | 69.1% | 69.1% | 71.3% |
Net Margin | 16.2% | 27.3% | 16.7% | 41.4% | 27.4% |
Return on Assets | 8.1% | 13.4% | 8.5% | 6.8% | 8.3% |
Return on Equity | 19.7% | 31.7% | 20.9% | 48.6% | 25.7% |
ROIC | 18.4% | 15.1% | 17.3% | 19.6% | 14.6% |
Additional data provided by Zacks, Intrinio, Quandl, Yodlee, IEX Cloud
JNJ has outperformed its sector by 26.0% in the past year.
The Healthcare sector has outperformed the market by 12.7% in the past year.